Quarterly ResultAug 10, 2026, 04:29 PM
Biohaven Q2 Net Loss $137.3M; Advances Pipeline
AI Summary
Biohaven Ltd. reported a net loss of $137.3 million, or $0.91 per share, for the second quarter ended June 30, 2026. Non-GAAP adjusted net loss was $118.1 million, or $0.78 per share. The company significantly advanced its pipeline, initiating a pivotal Phase 3 study for BHV-1300 in Graves' disease and expecting key data readouts for opakalim and taldefgrobep alfa in the second half of 2026. R&D and G&A expenses decreased compared to the prior year, and the company maintained a cash position of $270.5 million.
Key Highlights
- Reported Q2 2026 net loss of $137.3 million, or $0.91 per share.
- Non-GAAP adjusted net loss for Q2 2026 was $118.1 million, or $0.78 per share.
- R&D expenses decreased to $100.8 million in Q2 2026 from $184.4 million in Q2 2025.
- G&A expenses decreased to $24.1 million in Q2 2026 from $27.3 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $270.5 million as of June 30, 2026.
- Initiated pivotal Phase 3 study for BHV-1300 in Graves' disease.
- Topline results for opakalim Phase 2/3 trial in focal epilepsy expected 2H 2026.
- Patient enrollment completed for Phase 2 obesity study of taldefgrobep alfa, with data expected 2H 2026.
Price Impact
More from BHVN